Virtual Event | July 7, 2026

Solving Vector Yield Challenges in In Vivo CGT

Source: Cell & Gene

In this Cell & Gene Live, Chief Editor Erin Harris was joined by Robert Bell, Ph.D., CSO at Ascidian Therapeutics and Karen Kozarsky, Ph.D., President and CSO at Vector BioPartners, as they unpacked how capsid engineering decisions impact transduction efficiency, the tradeoffs between tissue specificity and manufacturability, and what manufacturing teams need to better understand about real-world in vivo performance, and more. 

access the Virtual Event!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)